** Brokerage Bernstein raises PT on medical device maker Insulet Corp PODD.O to $335 from $315
** New PT represents 18.5% upside to stock's last close
** Says it maintains "outperform" rating, adding its PT reflects increasing profitability
** Brokerage pointed several growth drivers for co, including integration of its Omnipod insulin pumps with Dexcom's DXCM.O G7 continuous glucose monitor, iOS compatibility with G5 devices, and launch an advanced version of insulin system
** Co's lead product is the Omnipod system, a tubeless, wearable insulin pump
** Co's revenue growth forecast of 17% to 21% is "conservative" and "we like the setup for 2025" - Bernstein
** Brokerage sees potential for growth driven by sales in type 2 diabetes market and expanding profit margins
** Stock has risen ~47% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。